Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Literature
1.
Rowner WS, Lui LY, Cummings SR (2001) Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631–637PubMed
2.
Cepok S, Jacobsen M, Schock S, Omer B, Jaekel S, Bödekker I, Örtel WH, Sommer N, Hemmer B (2001) Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 124:2169–2176CrossRefPubMed
3.
Emery JG, McDonnell P, Brigham Burke M, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–14367PubMed
4.
Hofbauer LC, Kluger S, Kühne CA, Dunstan CR, Schoppet M, Zielke A, Heufelder AE (2002) Role of receptor activator of NF-κB ligand and osteoprotegerin in the thyroid. J Cell Biochem 86:642–650CrossRefPubMed
5.
Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382–4389PubMed
6.
Kong Y-Y, Boyle WJ, Penninger JM (2000) Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 21:495–502CrossRefPubMed
7.
Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309PubMed
8.
Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J, Schenkel J, Herdegen T, Debatin KM (1999) CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809–3817PubMed
9.
Naumann U, Wick W, Beschorner R, Meyermann R, Weller M (2004) Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathol 107:17–22CrossRefPubMed
10.
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to stimulate bone destruction and promote tumor progression. Proc Natl Acad Sci (USA) 98:11581–11586CrossRef
11.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Eliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319PubMed
12.
Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 86:3162–3165
13.
Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B, Ellen RP, Penninger JM (2000) Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 106:R59–R67PubMed
14.
Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y (1999) Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14:518–527PubMed
Metadata
Title
Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid
Authors
Lorenz C. Hofbauer
Sabine Cepok
Bernhard Hemmer
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Acta Neuropathologica / Issue 6/2004
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-004-0854-y

Other articles of this Issue 6/2004

Acta Neuropathologica 6/2004 Go to the issue

Regular Paper

Evaluation of rapid tests for the diagnosis of transmissible spongiform encephalopathies in sheep and goats

Case Report

Pigmented central neurocytoma

Regular Paper

Blood-brain barrier is impaired in the hippocampus of young adult spontaneously hypertensive rats

Regular Paper

Purkinje cell neuroaxonal dystrophy similar to nervous mutant mice phenotype in two sibling kittens

Letter to the Editor

Reply to Lorenz et al.: Osteoprotegerin in the central nervous system

Regular Paper

Pathological properties of the Parkinson’s disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick’s disease